Core Viewpoint - The company announced the presentation of long-term efficacy and safety data for pimicotinib in treating patients with tenosynovial giant cell tumor (TGCT) at the 2025 ESMO conference, highlighting strong and durable tumor response rates and clinical improvements [1] Group 1: Study Results - The global Phase III MANEUVER study demonstrated strong and durable tumor response rates for pimicotinib, as assessed by the blinded independent review committee (BIRC) using RECIST v1.1 criteria and tumor volume scoring (TVS) [1] - Objective response rate (ORR) confirmed by the study indicates significant efficacy of pimicotinib in TGCT patients [1] Group 2: Clinical Outcomes - Clinical assessments showed meaningful and sustained improvements in joint mobility, stiffness, pain, and physical function among patients treated with pimicotinib [1] - The long-term feasibility of treatment with pimicotinib has been validated through consistent safety profiles compared to previous analyses [1]
和誉-B(02256.HK)：于2025年ESMO会议展示匹米替尼临床III期MANEUVER研究长期疗效和安全性数据